EHA 2022 | Reasons why there are fewer treatment options for MDS patients and hope for the future
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, briefly talks on reasons why there are fewer treatment options for patients with myelodysplastic syndromes (MDS) compared to other hematological malignancies, drawing focus on the heterogeneity of this disease and the importance of improving approaches in the future. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Receiving grant support, paid to GWT-TUD, from Amgen, lecture fees, grant support, paid to the University of Leipzig, fees for serving on a steering committee, consulting fees, and travel support from Celgene, grant support, paid to GWT-TUD, from Janssen Biotech, grant support, paid to University Dresden, from Merck and Novartis, and lecture fees from Novartis.
